Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

Table 4 Safety profile and side effects (grade 3 or 4) n (%)

Toxicities	Adjuvant group, n = 25 (100)	Neoadjuvant group, n = 13 (100)
Abdominal pain/pelvic pain	16 (64)	5 (38.5)
Nausea/vomiting	9 (36)	4 (30.8)
Fatigue	2 (8)	2 (15.4)
Renal insufficiency	0 (0)	3 (23.1)
Dehydration/hypotension	4 (16)	2 (15.4)
Catheter malfunction/infection	1 (4)	0 (0)
Anemia	3 (12)	1 (7.7)
Thrombocytopenia	1 (4)	0 (0)
Neutropenia	5 (20)	1 (7.7)
Hypokalemia	1 (4)	4 (30.8)
Hypomagnesemia	3 (12)	2 (15.4)